ALLERGIC RHINITIS AND ASTHMA :
|
|
- Alison Thomas
- 5 years ago
- Views:
Transcription
1 ALLERGIC RHINITIS AND ASTHMA : from the Link to Emerging Therapies Allergic rhinitis and asthma are both chronic heterogeneous disorders, with an overlapping epidemiology of prevalence, health care costs and social costs in quality of life (QoL). 1 It has long been recognized that allergic rhinitis and asthma commonly co-exist, due to their similarities in anatomy, physiology and immunopathology. 2 Patients can present with symptoms of allergic rhinitis then later develop asthma or the opposite can be the presenting scenario. According to the latest guidelines on the treatment and control of allergic rhinitis: The allergic rhinitis and its impact on asthma (ARIA) workshop report; bronchial asthma and allergic rhinitis are distinct manifestations of a single airway and of the same disease. 3 Epidemiological Link Epidemiological evidences and clinical as well as experimental observations have suggested a link between allergic rhinitis and asthma. Asthma and rhinitis, are rightly called the 21 st century epidemic and modern age diseases. The World Health Organization (WHO) estimates there are 300 million asthmatics in the world, and 500 million people with the symptoms of rhinitis. 4 To better understand the possible links between asthma and allergic rhinitis; the WHO, through the ARIA program, examined the impact of allergic rhinitis on asthma: major chronic respiratory disease owing to its prevalence, impact on QoL, impact on school and work performance and productivity and economic burden. According to the ARIA study and previous observations, allergic and non-allergic rhinitis should be considered as risk factors for asthma, along with other known risk factors. 5 The connection between allergic rhinitis and asthma has been the subject of many epidemiological investigations that have shown an important overlap between both diseases. 1 The 1st International Study of Asthma and Allergies in Childhood (ISAAC) study revealed the presence of asthma in 25 35% subjects with rhinitis, and rhinitis symptoms in 75 90% of asthmatics. Burgess et al. found that childhood allergic rhinitis was associated with a 7-fold increased risk of asthma in pre-adolescence (HR 7.12, 95 % CI ) and an over 4-fold increased risk of asthma in adolescence (HR 4.34, 95 % CI ). 6 In the early studies, 40% of allergic rhinitis patients had asthma, and 30% to 80% of asthmatic patients reported allergic rhinitis. A study of medical newsletter I as a service to the medical profession I 19
2 Nose (sinu)-bronchial reflex Postnasal drip Physical filter impairment Adhesion molecules Cytokines Epithelial cells Bone marrow Infections Inflammation Simons et al. suggested that these had probably underestimated the relationship, because more recent, sensitive interview protocols found rhinitis in 98.9% of allergic subjects with asthma and in 78.4% of non-allergic subjects with asthma. Leynaert et al. reviewed several studies demonstrating the strong association between rhinitis and asthma, both in allergic and non-allergic subjects. 1 Studies of both adult and pediatric populations provide evidence for increased risk of asthma development in individuals with allergic rhinitis. 7 expressed in both upper and lower airways. 5 Allergic Rhinitis, Airway Hyper responsiveness and Asthma: It is important to mention the frequent association of the nonspecific bronchial hyperresponsiveness with rhinitis. A possible, mechanism of the nonspecific reactivity is the so-called neurogenic inflammation, in which neuropeptides (substance P, neurokinin A) are involved. In fact, the regulation of capacitance vessels (and therefore the plasma extravasation and edema) is mainly due to sensory-neural apparatus. While most clinical and epidemiological observations suggest that the natural progression of the disease from the upper respiratory airways towards the lower ones, it has recently been demonstrated that segmental bronchial challenge is able to induce nasal symptoms as well as nasal inflammation in patients with allergic rhinitis. This latter aspect is difficult to interpret as there is no clinical situation in humans where a primary bronchial disease can result in a nasal disorder, but a systemic connection via the bone marrow may be a possible mechanism. 4 Allergens Figure 4.1: Physiopathological hypotheses explaining the concept of one airway disease Bronchial hyperreactivity Pathological Link The clearest connection between allergic rhinitis and asthma is based on a shared physiological response; both are part of the body s immune response to an identified foreign substance. The following section describes similarities and dissimilarities between rhinitis and asthma pathologies. 1 Inflammatory Response: The inflammatory response is similar for both allergic rhinitis and asthma; as share a similar respiratory epithelial structure. In allergic rhinitis, the immediate reaction leads to nasal congestion and runny nose from an increase in vascular permeability. In asthma, the immediate reaction results in bronchospasm. But in late-phase reaction mainly triggered by CD4+ T cells, asthma and allergic rhinitis occur following allergic exposure. There is a common cellular inflammation pattern characterized by eosinophil, mast-cell, and CD4+ T-cell infiltration. Mediators (including histamine; cysteinyl leukotrienes; interleukin [IL]-4 etc.) are Need for Integrated Disease Management for The common co-morbidities and shared pathophysiologies of asthma and allergic rhinitis have led to the concept of one airway, one disease and the need for a common therapeutic approach. To achieve optimal treatment for patients, it is the recommendation of the ARIA workshop group in collaboration with the WHO that patients with persistent allergic rhinitis should be evaluated for asthma, and that also patients with asthma should be evaluated for rhinitis. A strategy combining the treatment of both upper and lower airway disease in terms of efficacy and safety appears to be optimal (ARIA guidelines 2008). In many ways, leukotriene receptor antagonists (LTRAs) represent a rational approach to such one airway disease management (Figure 4.3). Leukotriene receptor antagonists are an established treatment option for asthma, with evidence to support their use in mild, persistant disease, pediatric asthma, exercise-induced bronchoconstriction, and in the tapering of inhaled corticosteroids (ICSs). Evidence is also accumulating in 20 I medical newsletter I as a service to the medical profession
3 % predicted FEV1 Mast cell mediator release Antigen Neutrophil influx and mediator release Eosinophil influx and mediator release Histamine, prostaglandins, leukotricnes and thromboxanes Time (hours) AR Asthma Severity of symptoms Figure 4.2 : Inflammatory cascade : Dual response in allergic rhinitis and asthma seasonal increase in nasal and lung symptoms. Controlled studies by Walsh and by Wilson show that the combination therapy with antihistamines and antileukotrienes is as effective as corticosteroid use in patients with allergic asthma and seasonal allergic rhinitis. The study by Roquet et al. gives evidence in favor of the use of antileukotrienes to treat asthma and rhinitis. However, more data are needed to understand their full capacity. The combination of antileukotriene and antihistamine produces an inhibition of allergen-induced early-and-late phase airway obstruction in asthmatics. 8 allergic rhinitis to suggest that both alone and in combination with an antihistamine, LTRAs like montelukast can alleviate the signs and symptoms of allergic rhinitis. 4 Emerging Therapeutic Strategies for Leukotriene receptor antagonists can be considered an established treatment option for asthma, with published clinical evidence for their efficacy and tolerability in this indication dating back to the early 1990s. More recently, evidence has also started to accumulate in support of their utility in the treatment of allergic rhinitis. Data are available for a number of the LTRAs (e.g. zafirlukast, pranlukast) but montelukast is the most studied LTRA in this respect. 4 The study by Nathan et al. evaluated patient with persistent asthma treated with the combination of fluticasone propionate and salmeterol. Adding montelukast or fluticasone propionate aqueous nasal spray for the treatment of seasonal allergic rhinitis resulted in no additional improvements in overall asthma control compared with the combination therapy with fluticasone and salmeterol alone. The combined use of budesonide nasal steroid with a leukotriene modifier, zafirlukast, was more effective for controlling nasal symptoms and especially bronchial symptoms than combined use of a nasal budesonide with loratadine plus pseudoephedrine. Dahl et al. have shown that in patients with pollen-induced allergic rhinitis and asthma the combination of nasal and inhaled glucocorticosteroids is needed to control the LTRAS in Combination with Antihistamines The combination of an antihistamine and an LTRA in the treatment of allergic rhinitis is based on the importance of both histamine and cysteinyl leukotrienes as mediators. In a 2-week study of 460 men and women with spring seasonal allergic rhinitis were randomized to one of five once-daily treatments: montelukast 10 mg; montelukast 20 mg; loratadine 10 mg; montelukast 10 mg plus loratadine 10 mg; or placebo. Concomitant montelukast and loratadine improved the primary endpoint significantly (p<0.001) compared with placebo and each agent alone. Topically administered intranasal steroids are widely recognized to be effective for the treatment of allergic rhinitis. A study by Wilson et al. compared the effects of 2 weeks of therapy with either 200 mg intranasal mometasone or 10 mg montelukast plus 10 mg certirizine, both once daily. Both mometasone and the combination of montelukast plus cetirizine produced significant (p<0.05) improvements versus placebo in nasal peak expiratory flow rate, nasal oral index, nasal symptoms, nasal itch and blockage, eye symptoms and daily activity score. Importantly, there were no significant differences between mometasone and montelukast plus cetirizine, both treatment regimens producing an approximate 50% reduction in nasal symptom scores (Table 4.1). The investigators concluded that oral montelukast plus cetirizine and intranasal mometasone provided equivalent objective and subjective clinical efficacy. 4 medical newsletter I as a service to the medical profession I 21
4 Rhinitis LTRAs HIs NCSs ICSs L.A. 2s specific immunotherapy allergen avoidance-education Figure 4.3: LTRAs in one airway one disease concept Mild, persistent asthma: LTRAS in Asthma Barnes et al. analyzed the use of montelukast in patients with mild, persistent asthma and found that it improved control of asthma parameters (eg, FEV 1 improved 7% to 8% over baseline). In some patients with stable asthma treated with inhaled corticosteroids, montelukast provides additional control of inflammation and improves QoL scores. Overall, this LTRA was demonstrated to be an effective and well-tolerated treatment. With the effectiveness of LTRAs in treating asthma, Meltzer reviewed the studies on the efficacy of zafirlukast and montelukast in asthma, and explored the use of LTRAs in allergic rhynitis. This study found that the montelukast was an effective treatment for allergic rhinitis. Montelukast produced a greater effect than placebo, demonstrating increases in FEV 1, reductions in rescue agonist use, decreased nocturnal awakenings, and more rescue-free days and a significant reduction in blood eosinophil count compared with placebo. 4 Pediatric asthma: Traditionally, ICS and cromolyn have been the controller treatments of choice for young children with persistent asthma. Knorr et al, reported the first, large multicenter study of an LTRA in children 2-5 years of age, in which they demonstrated that montelukast produced significant improvements versus placebo in multiple efficacy parameters (e.g. daytime/nighttime asthma symptoms, the percentage of asthma-free days, use of agonists or oral corticosteroids, physician global evaluations, and peripheral blood eosinophils). 4 Bisgaard et al. investigated the role of montelukast in the prevention of Asthma wheezing attacks induced by viral infection in children aged 2-5 years with intermittent asthma. The patients were randomized to receive montelukast or placebo for a 12-month period. The group with active treatment presented fewer symptoms and wheezing exacerbations. Spahn et al. have recently confirmed the effects of montelukast on peripheral airway obstruction and the concentration of eosinophilic cationic protein in children and adolescents with moderate asthma. Use of montelukast was associated with less air trapping, hyperinflation and resistance and higher values of spirometry and specific airway conductance as compared with placebo. 9 Exercise-induced asthma: Long-and short-acting agonists are typically used to control the symptoms of exercise induced asthma, but can be associated with the development of tolerance thereby decreasing efficacy. Leukotriene receptor antagonists do not exhibit any tachyphylaxis, and so may provide benefit in this respect. A study of 197 patients with mild asthma and a post-exercise fall in FEV 1 >18% comparing the effects of montelukast (10mg once-daily) with salmeterol (50mg twice daily) showed that the protection afforded by montelukast and salmeterol were similar at day 3 but only the effects of montelukast persisted throughout the 8 weeks of treatment without the development of tolerance. 4 Future Potential Therapies for Allergic Due to the co-existence of asthma and rhinitis, treatment strategies targeting both diseases is a major concern when developing new therapies. However, their potential use should be considered in the light of existing treatment like H1-antihistamines/intra-nasal steroids. One such therapeutic approach now under evaluation is the humanized monoclonal antibody against IgE. It is a monoclonal antibody raised against the Ce3 domain of IgE 22 I medical newsletter I as a service to the medical profession
5 Table 4.1 : Montelukast in Allergic Rhinitis 4 As monotherapy for allergic rhinitis, montelukast : Reduced daytime symptoms of allergic rhinitis Reduced nighttime symptoms of allergic rhinitis Reduced peripheral blood eosinophils Montelukast in combination with loratadine : Provided an additive effect on symptoms of allergic rhinitis Improved quality of life Montelukast in combination with cetirizine reduced total nasal symptoms to a similar extent as intranasal mometasone Table 4.2 : Montelukast in Asthma 4 In patients with mild persistent asthma, as an alternative choice, montelukast : Increased lung function (FEV 1 ) Reduced agonist use and nocturnal awakenings In patients on inhaled corticosteroids, as an add-on therapy, montelukast : Reduced the average daily dose of inhaled corticosteroids Maintained clinical stability with a lower dose of inhaled corticosteroids In pre-school aged children (2 to 5 years), as an add-on choice with ICS, montelukast : Improved a range of asthma symptoms Reduced the need for oral steroids Reduced inflammatory markers (peripheral blood eosinophils) In patients with exercise-induced asthma, montelukast maintained consistent reductions in EIB over the treatment period molecule is MaE11 and its humanized form used in clinical trials is the rhu-mab-e25 (E25). Other future potential therapies include monoclonal antibodies against IL-5, IL-4R antagonists; chemokine receptor inhibitors like the CCR3 receptor; ligand inhibitors such as VLA-4 antagonists; the CTLA4 fusion protein; recombinant allergens; peptide vaccines; the use of IL-12 as an adjuvant with specific immunotherapy; bacterial or mycobacterial products to stimulate Th1 response; and the plasmid DNA encoding of antigen. 4 Conclusion Allergic rhinitis is an important risk factor for developing asthma and is also an important cause of nonoptimal control of asthma. Links between upper- and lower-airway diseases exist through inflammatory mediators, but other mechanisms, such as mouth breathing and postnasal drip, can contribute. Allergic rhinitis and asthma often respond to the same treatments, which suggests that there is an intimate connection between the two. Many therapeutic options are currently available although antileukotrienes have beneficial effects on allergic rhinitis and asthma because they work through a systemic effect. References 1. H Kim, J Bouchard, PM Renzi. The link between allergic rhinitis and asthma: A role for antileukotrienes? Can Respir J 2008; 15(2): Groot EP, Nijkamp A, Duiverman EJ, Brand PLP. Allergic rhinitis is associated with poor asthma control in children with asthma. Thorax. 2012; 67: Daabis R. Allergic rhinitis and asthma: The united airways disease. Pulm Res Respir Med Open J. 2016; 3(2): e3-e4. 4. Pawankar R. Allergic rhinitis and asthma: from the link to emerging therapies. Indian J Chest Dis Allied Sci Jul-Sep; 45(3): Bergeron C, Hamid Q. Relationship between Asthma and Rhinitis: Epidemiologic, Pathophysiologic, and Therapeutic Aspects. Allergy Asthma Clin Immunol Jun 15; 1(2): Zvezdin B, Hromiš S, Kolarov V, et al. Allergic asthma and rhinitis comorbidity. Vojnosanit Pregl. 2015; 72(11): Egan M, Bunyavanich S. Allergic rhinitis: the Ghost Diagnosis in patients with asthma. Egan and Bunyavanich Asthma Research and Practice (2015) 1:8. Available from: com/articles/ /s Valovirta E. Managing Co-Morbid Asthma with Allergic Rhinitis: Targeting the One-Airway With Leukotriene Receptor Antagonists. WAO Journal. 2012; 5:S210 S Ribeiro JD, Toro AA, Baracat EC. Antileukotrienes in the treatment of asthma and allergic rhinitis. J Pediatr (Rio J). 2006;82(5 Suppl): S medical newsletter I as a service to the medical profession I 23
Dual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationImmunology of Asthma. Kenneth J. Goodrum,Ph. Ph.D. Ohio University College of Osteopathic Medicine
Immunology of Asthma Kenneth J. Goodrum,Ph Ph.D. Ohio University College of Osteopathic Medicine Outline! Consensus characteristics! Allergens:role in asthma! Immune/inflammatory basis! Genetic basis!
More informationScottish Medicines Consortium
Scottish Medicines Consortium montelukast 10mg tablets (Singulair ) No. (185/05) Merck, Sharp & Dohme Ltd (MSD) New indication: for asthmatic patients in whom montelukast is indicated in asthma, montelukast
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More informationImpact of Asthma in the U.S. per Year. Asthma Epidemiology and Pathophysiology. Risk Factors for Asthma. Childhood Asthma Costs of Asthma
American Association for Respiratory Care Asthma Educator Certification Prep Course Asthma Epidemiology and Pathophysiology Robert C. Cohn, MD, FAARC MetroHealth Medical Center Cleveland, OH Impact of
More informationEfficacy and safety of montelukast in adults with asthma and allergic rhinitis
Respiratory Medicine (26), 1952 1959 Efficacy and safety of montelukast in adults with asthma and allergic rhinitis J.Chr. Virchow a,, C. Bachert b a Universität Rostock, Ernst-Heydemann-Str. 6, 1857 Rostock,
More informationAsthma Management for the Athlete
Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric
More informationASTHMA. Epidemiology. Pathophysiology. Diagnosis. IAP UG Teaching slides
BRONCHIAL ASTHMA ASTHMA Epidemiology Pathophysiology Diagnosis 2 CHILDHOOD ASTHMA Childhood bronchial asthma is characterized by Airway obstruction which is reversible Airway inflammation Airway hyper
More informationAir Flow Limitation. In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation.
Asthma Air Flow Limitation In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation. True whether reversible, asthma and exercise-induced bronchospasm,
More informationImplications on therapy. Prof. of Medicine and Allergy Faculty of Medicine, Cairo University
Implications on therapy Dr. Hisham Tarraf MD,FRCP(Edinb.) Prof. of Medicine and Allergy Faculty of Medicine, Cairo University Need for better understanding Global health problem Impact on quality of life
More informationAn Update on Allergic Rhinitis. Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital
An Update on Allergic Rhinitis Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital Allergic Rhinitis Common condition with increasing prevalence
More informationAsthma and Vocal Cord Dysfunction
Asthma and Vocal Cord Dysfunction Amy L. Marks DO, FACOP Pediatric Allergy and Immunology Assistant Professor of Pediatrics Oakland University William Beaumont School of Medicine Objectives: Understanding
More informationClinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy
Clinical Implications of Asthma Phenotypes Michael Schatz, MD, MS Department of Allergy Definition of Phenotype The observable properties of an organism that are produced by the interaction of the genotype
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationClinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis
Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Kim Hyun Hee, MD, PhD. Dept. of Pediatrics The Catholic University of Korea College of Medicine Achieving
More information31 - Respiratory System
31 - Respiratory System Asthma 1. Asthma has two components. Name the two components. 2. What are the common triggers of asthma? (LP p319) (e.g., pets) Upper respiratory infections ( ) 3. Describe a normal
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationDerriford Hospital. Peninsula Medical School
Asthma and Allergic Rhinitis iti What is the Connection? Hisham Khalil Consultant ENT Surgeon Clinical Senior Lecturer, PMS Clinical Sub-Dean GP Evening 25 June 2008 Plymouth Derriford Hospital Peninsula
More informationAsthma Pathophysiology and Treatment. John R. Holcomb, M.D.
Asthma Pathophysiology and Treatment John R. Holcomb, M.D. Objectives Definition of Asthma Epidemiology and risk factors of Asthma Pathophysiology of Asthma Diagnostics test of Asthma Management of Asthma
More informationAllergy and inflammation
and inflammation 1 Allergic population hyper-producers of IgE consistently increasing western societies: ~20% of general population 2 Allergic population 3 Allergic triggers 4 Allergic triggers abnormal
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAllergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al.
Allergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al. Chapter 75: Approach to Infants and Children with Asthma
More informationXolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
More informationAsthma in Pediatric Patients. DanThuy Dao, D.O., FAAP. Disclosures. None
Asthma in Pediatric Patients DanThuy Dao, D.O., FAAP Disclosures None Objectives 1. Discuss the evaluation and management of asthma in a pediatric patient 2. Accurately assess asthma severity and level
More informationOmalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
More informationARIA. At-A-Glance Pocket Reference 2007
ARIA_Glance_2007_8pg:ARIA_Glance_English 9/14/07 3:10 PM Page 1 ARIA At-A-Glance Pocket Reference 2007 1 st Edition NEW ARIA UPDATE BASED ON THE ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA WORKSHOP REPORT
More informationEfficacy and Safety of Montelukast as Monotherapy in Children with Mild Persistent Asthma. Gautam Ghosh, Arun Kumar Manglik and Subhasis Roy
Efficacy and Safety of Montelukast as Monotherapy in Children with Mild Persistent Asthma Gautam Ghosh, Arun Kumar Manglik and Subhasis Roy From the Shree Jain Hospital & Research Center, Howrah 711 102
More informationCurrent Asthma Management: Opportunities for a Nutrition-Based Intervention
Current Asthma Management: Opportunities for a Nutrition-Based Intervention Stanley J. Szefler, MD Approximately 22 million Americans, including 6 million children, have asthma. It is one of the most prevalent
More informationAllergies and Asthma 5/21/2013. Objectives. Allergic Rhinitis (AR): Risk Factor for ASTHMA. Rhinitis and Asthma
Allergies and Asthma Presented By: Dr. Fadwa Gillanders, Pharm.D Clinical Pharmacy Specialist May 2013 Objectives Understand the relationship between asthma and allergic rhinitis Understand what is going
More informationLearning the Asthma Guidelines by Case Studies
Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma
More informationBronchial asthma. MUDr. Mojmír Račanský Odd. Alergologie a klinické imunologie FNOL Ústav Imunologie LF UPOL
Bronchial asthma MUDr. Mojmír Račanský Odd. Alergologie a klinické imunologie FNOL Ústav Imunologie LF UPOL DEFINITION ASTHMA BRONCHIALE = Asthma is a chronic inflammatory disorder of the airways in which
More informationFunction of the Respiratory System. Exchange CO2 (on expiration) for O2 (on inspiration)
Function of the Respiratory System Exchange CO2 (on expiration) for O2 (on inspiration) Upper Respiratory Tract Includes: Nose Mouth Pharynx Larynx Function: Warms and humidifies the inspired air Filters
More informationDiagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma
More informationAsthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)
Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of
More informationBiologic Agents in the treatment of Severe Asthma
Biologic Agents in the treatment of Severe Asthma Daniel L Maxwell, D.O., FACOI, FAASM Clinical Assistant Professor of Medicine Michigan State University College of Osteopathic Medicine College of Human
More informationMeeting the Challenges of Asthma
Presenter Disclosure Information 11:05 11:45am Meeting the Challenge of Asthma SPEAKER Christopher Fanta, MD The following relationships exist related to this presentation: Christopher Fanta, MD: No financial
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2016?
Global Initiative for Asthma (GINA) What s new in GINA 2016? GINA Global Strategy for Asthma Management and Prevention GINA: A Brief History Established in 1993 Collaboration between NHLBI and WHO Multiple
More informationAsthma Description. Asthma is a disease that affects the lungs defined as a chronic inflammatory disorder of the airways.
Asthma Asthma Description Asthma is a disease that affects the lungs defined as a chronic inflammatory disorder of the airways. Symptoms of asthma In susceptible individuals, this inflammation causes recurrent
More informationManagement of asthma in preschool children with inhaled corticosteroids and leukotriene receptor antagonists Leonard B. Bacharier
Management of asthma in preschool children with inhaled corticosteroids and leukotriene receptor antagonists Leonard B. Bacharier Department of Pediatrics, Division of Allergy and Pulmonary Medicine, Washington
More informationEfficacy of Levocetirizine Compared with Montelukast for the Treatment of Allergic Rhinitis
Human Journals Research Article July 2018 Vol.:10, Issue:1 All rights are reserved by Manju K Mathew et al. Efficacy of Levocetirizine Compared with Montelukast for the Treatment of Allergic Rhinitis Keywords:
More informationInternational Journal of Medical Science and Education pissn eissn
COMPARISON OF MONTELUKAST AND KETOTIFEN AS ADD ON THERAPY IN MODERATE AND SEVERE PERSISTENT BRONCHIAL ASTHMA Dr. Gaurav Chhabra 1, Dr. Shubhakaran Sharma 2* Original research article 1,2 Associate professor,
More informationDoes rhinitis. lead to asthma? Does sneezing lead to wheezing? What allergic patients should know about the link between allergic rhinitis and asthma
Does rhinitis lead to asthma? Does sneezing lead to wheezing? What allergic patients should know about the link between allergic rhinitis and asthma For a better management of allergies in Europe Allergy
More informationPharmacotherapy for Allergic Rhinitis
Pharmacotherapy for Allergic Rhinitis William Reisacher, MD FACS FAAOA Assistant Professor Weill Cornell Medical College The Impact of Allergic Rhinitis Allergic rhinitis affects approximately 50 million
More informationBronchial asthma. E. Cserháti 1 st Department of Paediatrics. Lecture for english speaking students 5 February 2013
Bronchial asthma E. Cserháti 1 st Department of Paediatrics Lecture for english speaking students 5 February 2013 Epidemiology of childhood bronchial asthma Worldwide prevalence of 7-8 and 13-14 years
More informationEmily DiMango, MD Asthma II
Emily DiMango, MD Asthma II Director John Edsall/John Wood Asthma Center Columbia University Medical Center HP 2000 Goal: 2.25/1,000 Comparison of Asthma Hospitalization Rates in Children Aged 0-14 in
More informationDR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL
DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis
More informationOn completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
More informationManagement of Bronchial Asthma in Adults..emerging role of anti-leukotriene
Management of Bronchial Asthma in Adults..emerging role of anti-leukotriene Han-Pin Kuo MD, PhD Department of Thoracic Medicine Chang Gung University Chang Gung Memorial Hospital Taipei, Taiwan Bronchial
More informationSystems Pharmacology Respiratory Pharmacology. Lecture series : General outline
Systems Pharmacology 3320 2017 Respiratory Pharmacology Associate Professor Peter Henry (Rm 1.34) Peter.Henry@uwa.edu.au Division of Pharmacology, School of Biomedical Sciences Lecture series : General
More informationRole of Leukotriene Receptor Antagonists in the Treatment of Exercise-Induced Bronchoconstriction: A Review
Review Article Role of Leukotriene Receptor Antagonists in the Treatment of Exercise-Induced Bronchoconstriction: A Review George S. Philteos, MD, FRCP(C); Beth E. Davis, BSc; Donald W. Cockcroft, MD,
More informationJames P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren, MD
Therapeutic Effect of Zafirlukast as Monotherapy in Steroid-Naive Patients With Severe Persistent Asthma* James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren,
More informationAsthma for Primary Care: Assessment, Control, and Long-Term Management
Asthma for Primary Care: Assessment, Control, and Long-Term Management Learning Objectives After participating in this educational activity, participants should be better able to: 1. Choose the optimal
More informationDistinction and Overlap. Allergy Dpt, 2 nd Pediatric Clinic, University of Athens
Asthma Phenotypes: Distinction and Overlap Nikos Papadopoulos Allergy Dpt, 2 nd Pediatric Clinic, University of Athens Asthma as a syndrome From the Iliad to ADAM 33 and back again Bronchoconstriction,
More informationPotent and Selective CRTh2 Antagonists are Efficacious in Models of Asthma, Allergic Rhinitis and Atopic Dermatitis
Potent and Selective CRTh2 Antagonists are Efficacious in Models of Asthma, Allergic Rhinitis and Atopic Dermatitis Laura L. Carter, Yoshi Shiraishi, Yooseob Shin, Laurence Burgess, Christine Eberhardt,
More informationE-1 Role of IgE and IgE receptors in allergic airway inflammation and remodeling
E-1 Role of IgE and IgE receptors in allergic airway inflammation and remodeling Ruby Pawankar, MD, Ph.D. FRCP, FAAAAI Prof. Div of Allergy, Dept of Pediatrics Nippon Medical School Tokyo, Japan pawankar.ruby@gmail.com
More informationAsthma. Rachel Miller, MD, FAAAAI Director Allergy and Immunology New York Presbyterian Hospital. Figure 1 Asthma Prevalence,
Asthma Rachel Miller, MD, FAAAAI Director Allergy and Immunology New York Presbyterian Hospital Figure 1 Asthma Prevalence, 1980-2000 * Gap between 1995-1996 and 1997 indicates a break in trend due to
More informationClinical trial efficacy: What does it really tell you?
Clinical trial efficacy: What does it really tell you? Joseph Spahn, MD Denver, Colo The primary goal of most clinical trials is an evaluation of the efficacy of the drug being evaluated. Therefore, it
More informationRespiratory Pharmacology
Allergy Targets of allergies Type I Histamine Leukotrienes Prostaglandins Bradykinin Hypersensitivity reactions Asthma Characterised by Triggered by Intrinsic Extrinsic (allergic) Mediators Result Early
More informationPredicting, Preventing and Managing Asthma Exacerbations. Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa
Predicting, Preventing and Managing Asthma Exacerbations Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa Asthma exacerbations Predicting exacerbation recognising
More informationRespiratory Health L O O K, F E E L A N D L I V E B E T T E R
LOOK, FEEL AND LIVE BET TER Respiratory health: hay-fever and asthma Airway obstruction and symptoms in asthma and hay-fever alike are the result of inappropriate responses of the body s immune system
More informationPhototherapy in Allergic Rhinitis
Phototherapy in Allergic Rhinitis Rhinology Chair KSU KAUH Ibrahim AlAwadh 18\1\2017 MBBS, SB & KSUF Resident, ORL-H&N Background: Endonasal phototherapy can relieve the symptoms of allergic rhinitis
More informationLatest advances in the management of childhood allergic rhinitis
Latest advances in the management of childhood allergic rhinitis Jason Y K Chan Assistant Professor Department of Otorhinolaryngology, Head & Neck Surgery The Chinese University of Hong Kong Disclosures
More informationTreatment Of Allergic Rhinitis
Treatment Of Allergic Rhinitis 1 / 6 2 / 6 3 / 6 Treatment Of Allergic Rhinitis Galphimia Glauca, Histaminum Hydrochlo-ride, Cardiospermum Halicacabum and Amni Visnaga are effective homeopathic medicines
More informationSafety, PK and PD of ARRY-502, a CRTh2 Antagonist, in Healthy Subjects with a History of Seasonal Allergies
Safety, PK and PD of ARRY502, a CRTh2 Antagonist, in Healthy Subjects with a History of Seasonal Allergies L. Burgess*, L. Anderson, C. Nugent, N. Klopfenstein, C. Eberhardt, L. Carter, C. Kass, S. RojasCaro,
More informationNew Therapies for Asthma
New Therapies for Asthma Tracy Bridges, MD Speaker Disclosure: Dr. Bridges participates in speaker bureaus for Teva, Genetech & Astra Zeneca. Objectives: Discuss the use of LAMA s for Asthma Detail the
More informationDo We Need Biologics in Pediatric Asthma Management?
Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by
More informationAsthma: Chronic Management. Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015
Asthma: Chronic Management Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015 Global Strategy for Asthma Management and Prevention Evidence-based Implementation
More informationThe Acute & Maintenance Treatment of Asthma via Aerosolized Medications
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.
More informationMontelukast in the treatment of asthma and beyond
For reprint orders, please contact reprints@expert-reviews.com Montelukast in the treatment of asthma and beyond Expert Rev. Clin. Immunol. 5(6), 639 658 (2009) Zuzana Diamant, Eva Mantzouranis and Leif
More informationSignificance. Asthma Definition. Focus on Asthma
Focus on Asthma (Relates to Chapter 29, Nursing Management: Obstructive Pulmonary Diseases, in the textbook) Asthma Definition Chronic inflammatory disorder of airways Causes airway hyperresponsiveness
More informationMatt Stumpe, MD Otolaryngologist Mid Kansas Ear, Nose, & Throat
Matt Stumpe, MD Otolaryngologist Mid Kansas Ear, Nose, & Throat Inflammation of the nasal mucosa secondary to an inappropriate hypersensitivity reaction to an allergen IgE mediated immune response with
More informationChildhood Asthma. The pathophysiology of asthma is an interplay. CME Case Study. Case Study. By Moyez B. Ladhani, MD, CCFP, FAAP, FRCPC
CME Case Study Childhood Asthma By Moyez B. Ladhani, MD, CCFP, FAAP, FRCPC Case Study A two-year-old child presents to your office with a cough, which has been present for three weeks. It is worse at nighttime
More informationCase Study. Allergic Rhinitis 5/18/2015
John A. Fling, M.D. Professor Allergy/Immunology University of North Texas Health Science Center, Fort Worth, Texas Case Study 38 year old male with a history of nasal congestion, clear nasal discharge
More informationASTHMA IN THE PEDIATRIC POPULATION
ASTHMA IN THE PEDIATRIC POPULATION SEARCH Rotation 2 August 23, 2010 Objectives Define asthma as a chronic disease Discuss the morbidity of asthma in pediatrics Discuss a few things that a health center
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationAirway Inflammation in Asthma Chih-Yung Chiu 1,2, Kin-Sun Wong 2 1 Department of Pediatrics, Chang Gung Memorial Hospital, Keelung, Taiwan.
REVIEW ARTICLE Chih-Yung Chiu 1,2, Kin-Sun Wong 2 1 Department of Pediatrics, Chang Gung Memorial Hospital, Keelung, Taiwan. 2 Division of Pediatric Pulmonology, Department of Pediatrics, Chang Gung Memorial
More informationExhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma
Exhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma Jason Debley, MD, MPH Assistant Professor, Pediatrics Division of Pulmonary Medicine University of Washington School of
More informationTREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN. Dr Lại Lê Hưng Respiratory Department
TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN Dr Lại Lê Hưng Respiratory Department Literature review current through: Feb 2013. This topic last updated: Aug 14, 2012 INTRODUCTION Wheezing
More informationThe Asthma Guidelines: Diagnosis and Assessment of Asthma
The Asthma Guidelines: Diagnosis and Assessment of Asthma Christopher H. Fanta, M.D. Partners Asthma Center Brigham and Women s Hospital Harvard Medical School Objectives Know how the diagnosis of asthma
More informationClinical Practice Guideline: Asthma
Clinical Practice Guideline: Asthma INTRODUCTION A critical aspect of the diagnosis and management of asthma is the precise and periodic measurement of lung function both before and after bronchodilator
More informationIs reslizumab effective in improving quality of life and asthma control in adolescent and adult patients with poorly controlled eosinophilic asthma?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2018 Is reslizumab effective in improving
More informationSLIT: Review and Update
SLIT: Review and Update Disclosure Speaker: ISTA Pharmaceuticals Speaker: GlaxoSmithKline Allergen IT - Evidence Based Evaluation: Rescue Medications Meta-analysis Disease IT # of Patients Rescue Medication
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationPRINCIPAL MEDICATION OPTIONS FOR RHINITIS
SEE INDICATED SUMMARY STATEMENT (SS#) DISCUSSION FOR SUPPORTING DATA ALLERGIC RHINITIS (AR): SEASONAL (SAR) AND PERENNIAL (PAR) MONOTHERAPY ORAL Antihistamines, oral (H1 receptor antagonists) (SS# 61-64)
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Omalizumab Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 6 References... 7 Effective Date... 3/15/2018 Next
More informationII: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
More informationScottish Medicines Consortium
Scottish Medicines Consortium Standardised allergen extract of grass pollen from Timothy (Phleum pratense) 75,000 SQ-T per oral lyophilisate (Grazax ) No. (367/07) ALK-Abellό Ltd 6 April 2007 The Scottish
More informationAmanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ
Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ Financial Disclosures Advanced Practiced Advisory Board for Circassia Learning Objectives 1. Briefly
More informationDecember 7, 2010 Future Use of Biologics in Allergy and Asthma
December 7, 2010 Future Use of Biologics in Allergy and Asthma Lanny J. Rosenwasser, M.D. Dee Lyons/Missouri Endowed Chair in Immunology Research Professor of Pediatrics Allergy-Immunology Division Childrens
More informationDr ARIF AHMED M.D.(Paed.), D.Ch., M.D.(USA), European Board (EACCI) Certified in Allergy & Immunology
Case Based Approach to Allergic Unified Airway Diseases Dr ARIF AHMED M.D.(Paed.), D.Ch., M.D.(USA), European Board (EACCI) Certified in Allergy & Immunology Recent Advances in Pediatrics 23: Hot Topics
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationMedications Affecting The Respiratory System
Medications Affecting The Respiratory System Overview Asthma is a chronic inflammatory disorder of the airways. It is an intermittent and reversible airflow obstruction that affects the bronchioles. The
More informationAllergic Rhinitis and Asthma : From the Link to Emerging Therapies
REVIEW ARTICLE Allergic Rhinitis and Asthma : From the Link to Emerging Therapies Department of Otolaryngology, Nippon Medical School, Tokyo, Japan ABSTRACT Epidemiological evidences and clinical as well
More informationPathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma
Allergy 2001: 56: Suppl. 66: 7 11 Printed in UK. All rights reserved Copyright # Munksgaard 2001 ALLERGY ISSN 0108-1675 Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor
More informationViral-Induced Asthma:
Viral-Induced : Sorting through the Studies Malcolm R. Sears, MB, FRACP, FRCPC Presented at the Respirology Update Continuing Education Program, January 2005 Viral-associated wheezing is common and not
More informationDr Rodney Itaki Lecturer Division of Pathology Anatomical Pathology Discipline
Pathology of Asthma Dr Rodney Itaki Lecturer Division of Pathology Anatomical Pathology Discipline Bronchial Asthma Definition: chronic, relapsing inflammatory lung disorder characterised by reversible
More informationRobert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network
Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network Robert.kruklitis@lvh.com Correlation of a Asthma pathophyisology with basic science Asthma (Physiology) Bronchodilators
More informationMonocast Description Indications
Monocast Tablet Description The active ingredient of Monocast tablet is Montelukast Sodium INN. Montelukast is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl
More information